The Headline:With longer follow-up SERENA-6 continues to break ground in the frontier of circulating tumor (ct)DNA-guided early systemic therapy changes. An updated analysis demonstrates nearly one-third of women who switched to camizestrant per emergent ESR1-mutations on ctDNA surveillance remain without progression at 30 months and enjoyed a significantly longer median time until chemo initiation. | Clement Bidard, ASCO 2026
